Peter Altmann, CEO of Biocardia, and Matthew Kalbermatten, CEO of Cellprothera, comment on the trans-endocardial intramyocardial delivery system and the importance of the right delivery solution for biotherapeutics to treat heart failure, ischemia and myocardial infarction.
Local intramyocardial delivery (IMD) expands the therapeutic window of cell, gene and protein-based therapies by maximizing targeted dose and minimizing dose at remote sites where toxic effects can occur. The intracoronary artery (ICA) delivers infusion agents to the well-perfused tissues of the heart. For agents that are small (gene therapy, proteins, and many cells), these agents will pass rapidly through the heart with little local benefit. For agents that are large, such as cultured expanded mesenchymal stem cells or cell aggregates, these large agents will first be inhibited in the capillary bed before they enter the well-perfused areas of the heart, achieving microvascular obstruction.
Because most animal research on local delivery of cell, gene, and protein therapies used IMD delivery and most clinical research on these agents used coronary artery infusion, translation from animals to humans has been very difficult. Something is lost. Several previous clinical trials using ICA delivery over the past two decades could be significantly enhanced with IMD.
Interventional cardiologists realized that they could minimally invasively deliver biotherapeutics to the heart muscle with specialized transendocardial IMD catheters from within the heart, avoiding the limitations of ICA infusions. The motivation for this was to increase local biodistribution where it is needed – not just where the cells or genes would go after entering the blood vessel. Here, a catheter is advanced retrogradely through the aortic valve and delivered to certain heart segments relative to areas of infarction or ischemia.
Transendocardial IMD (TE-IMD) development continues to address the issue of catheter over all safety and efficiency of delivery. This has the advantages of avoiding back leakage of the injection into the ventricular chamber and enhancing navigation within the left ventricle of the heart in terms of device control and imaging.
A review of the safety of delivery systems for cell and gene-based therapies for the heart with the treatment of the emerging major adverse cardiac and cerebrovascular event (MACCE) profile is shown below, where each delivery approach was used in hundreds of patients ( i).
Cardiac perforation was reported to be the primary cause of MACCE with TEIMD. The primary cause of MACCE for the stop flow ICA technique was reported as vascular obstruction. There was also mortality with other methods not seen with stop flow and helix. An additional review by Rawal (2021)(i) also revealed that the Helix catheter had a reported MACCE of 1/3 relative to its next closest catheter, the JNJ MyoStar. Only in the post-acute myocardial infarction setting, where there have been two small studies, one with MyoStar and one with the Helix TEIMD system, has there been zero treatment emergent MACCE.
Delivery efficiency is also important and Mitsutake (ii) has reported excellent experimental results using PET/CT to quantify the delivery of 18F-FDG labeled mononuclear cells (comprising CD34+ cells) that have been identified by radioactivity. – Labelled. The quantification approach was enhanced by normalizing the signal with a vial of the same cells taped to the animal’s chest. Results show an average threefold efficiency with the Helix TEIM catheter compared to straight needle transepicardial intramyocardial delivery and eighteenfold the retention achieved with ICA. It has been hypothesized that the increased retention caused by the helical needle is due to its longer self-sealing passage through the tissue while attached to the heart and these results have been confirmed by other groups with other agents.
This attachment to the heart provides the physician with the ability to control the timing of the infusion and is believed to reduce leakage back into the ventricular chamber that has been shown with other straight needle TEIM catheter platforms. Those considering cell aggregates and biopolymers may benefit greatly from these aspects as increased retention may correlate well with increased safety.
Today the Helix TEIM catheter system is being advanced in clinical trials of autologous and allogeneic cell therapy for heart failure and chronic myocardial ischemia by Biocardia and after acute myocardial infarction by Cellprothera. Successful delivery has the potential to significantly enhance the therapeutic efficacy outcomes of each of these programs. For Biocardia’s programs, there are other similar straight needle programs from which we can estimate what may contribute to the threefold dose increase due to delivery efficiency. For Cellprothera’s clinical development program, there is great promise over the limits of ICA infusion at eighteen times the targeted dose. Cellprothera is actually testing a unique combination of its cellular product in a soon to be completed Phase 1/2B study that includes high doses of purified expanded stem cells with the high retention rate Helix TEIM catheter system. Significant enhancements are also underway to the Helix platform that are intended to benefit all ongoing programs and further other clinical partners.
(i) Rawal AN and Pepin CJ. Clinical Safety Profile of Transendocardial Catheter Injection Systems: A Plea for Uniform Reporting, Cardiovascular Revascularization Medicine 22 (2021) 100-108.
(ii) Mitsutake Y, Pune WB, Ruy D. et al. Improving local cell delivery using helix
Transendocardial delivery catheter in the porcine heart, Int Heart J. 2017; 58: 1-6.
(i) Duckers H, Rawal A, Pepin C, et al. Performance of the Helix transendocardial biotherapeutic delivery system after 300 cases, TCT 2018 (Poster).











